Mental disorders associated with the novel coronavirus infection coronavirus disease-2019
- Authors: Bardenshteyn L.M.1, Aleshkina G.A.1, Pugacheva M.E.1, Kruglikova I.I.1
-
Affiliations:
- A.I. Evdokimov Moscow State University of Medicine and Dentistry
- Issue: Vol 27, No 4 (2021)
- Pages: 395-406
- Section: Reviews
- URL: https://journals.rcsi.science/0869-2106/article/view/106292
- DOI: https://doi.org/10.17816/0869-2106-2021-27-4-395-406
- ID: 106292
Cite item
Abstract
This study presents data from recent publications on the occurrence of mental disorders during the coronavirus disease-2019 (COVID-19) pandemic and the specifics of providing mental health care under social isolation conditions. The issues of negative psychopathological outcome prevention in persons with high-risk mental disorders are considered, as well as the problems of organizing psychiatric care provision during the pandemic, including the possibility of remote counseling and follow-up. The questions of the pathogenesis of psychopathological symptoms in coronavirus infection are discussed. Particular attention is paid to the adverse effects of COVID-19 therapy, psychotropic drugs interactions, and drug treatment for patients with coronavirus infection. The research results and opinions of Russian and international specialists in the field of mental health that are presented in this review are relevant for medical practitioners working in the pandemic.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Leonid M. Bardenshteyn
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: barden@mail.ru
ORCID iD: 0000-0002-1171-5517
MD, Dr. Sci. (Med.), Professor
Russian Federation, MoscowGalina A. Aleshkina
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: aleshkina-ga@yandex.ru
ORCID iD: 0000-0002-8872-9810
MD, Dr. Sci. (Med.), assistant professor, Professor
Russian Federation, MoscowMargarita E. Pugacheva
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Author for correspondence.
Email: theoreticusempiricus@yandex.ru
ORCID iD: 0000-0001-5956-5768
аssistant lecturer
Russian Federation, MoscowIrina I. Kruglikova
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: irenkruglikova@rambler.ru
ORCID iD: 0000-0002-9404-3452
Russian Federation, Moscow
References
- Kelly BD. Coronavirus disease: challenges for psychiatry. Br J Psychiatry. 2020;217(1):352–353. doi: 10.1192/bjp.2020.86
- Li Z, Ge J, Yang M, et al. Vicarious traumatization in the general public, members, and non-members of medical teams aiding in COVID-19 control. Brain Behav Immun. 2020;88:916–919. doi: 10.1016/j.bbi.2020.03.007
- Sorokin MY, Kas'yanov ED, Rukavishnikov GV, et al. Struktura trevozhnykh perezhivanii, assotsiirovannykh s rasprostraneniem COVID-19: dannye onlain-oprosa. Vestnik RGMU. 2020;(3):74–84. (In Russ). doi: 10.24075/vrgmu.2020.030
- Goularte JF, Serafim SD, Colombo R, et al. COVID-19 and mental health in Brazil: Psychiatric symptoms in the general population. J Psychiatr Res. 2021;132:32–37. doi: 10.1016/j.jpsychires.2020.09.021
- Mosolov SN. Aktual'nye zadachi psikhiatricheskoi sluzhby v svyazi s pandemiei COVID-19. Sovremennaya terapiya psikhicheskikh rasstroistv. 2020;(2):26–32. (In Russ). doi: 10.21265/PSYPH.2020.53.59536
- Roy D, Tripathy S, Kar SK, et al. Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic. Asian J Psychiatr. 2020;51:102083. doi: 10.1016/j.ajp.2020.102083
- Qiu J, Shen B, Zhao M, et al. A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations. Gen Psychiatr. 2020;33(2):e100213. doi: 10.1136/gpsych-2020-100213
- Abba-Aji A, Li D, Hrabok M, et al. COVID-19 Pandemic and Mental Health: Prevalence and Correlates of New-Onset Obsessive-Compulsive Symptoms in a Canadian Province. Int J Environ Res Public Health. 2020;17(19). doi: 10.3390/ijerph17196986
- Karatzias T, Shevlin M, Murphy J, et al. Posttraumatic Stress Symptoms and Associated Comorbidity During the COVID-19 Pandemic in Ireland: A Population-Based Study. J Trauma Stress. 2020;33(4):365–370. doi: 10.1002/jts.22565
- Sallie SN, Ritou V, Bowden-Jones H, Voon V. Assessing international alcohol consumption patterns during isolation from the COVID-19 pandemic using an online survey: highlighting negative emotionality mechanisms. BMJ Open. 2020;10(11):e044276. doi: 10.1136/bmjopen-2020-044276
- Shi L, Lu ZA, Que JY, et al. Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic. JAMA Netw Open. 2020;3(7):e2014053. doi: 10.1001/jamanetworkopen.2020.14053
- Haider, II, Tiwana F, Tahir SM. Impact of the COVID-19 Pandemic on Adult Mental Health. Pak J Med Sci. 2020;36(COVID19-S4):S90–S94. doi: 10.12669/pjms.36.COVID19-S4.2756
- Kaufman KR, Petkova E, Bhui KS, Schulze TG. A global needs assessment in times of a global crisis: world psychiatry response to the COVID-19 pandemic. BJPsych Open. 2020;6(3):e48. doi: 10.1192/bjo.2020.25
- Vasileva AV. Pandemic and mental adjustment disorders. Therapy options. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(5):146–152. (In Russ). doi: 10.17116/jnevro2020120051146
- Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry. 2003;54(9):906–914. doi: 10.1016/s0006-3223(03)00173-2
- Haapakoski R, Mathieu J, Ebmeier KP, et al. Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. Brain Behav Immun. 2015;49:206–215. doi: 10.1016/j.bbi.2015.06.001
- Arteaga-Henriquez G, Simon MS, Burger B, et al. Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. Front Psychiatry. 2019;10:458. doi: 10.3389/fpsyt.2019.00458
- Passos IC, Vasconcelos-Moreno MP, Costa LG, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry. 2015;2(11):1002–1012. doi: 10.1016/S2215-0366(15)00309-0
- Bauer ME, Teixeira AL. Inflammation in psychiatric disorders: what comes first? Ann N Y Acad Sci. 2019;1437(1):57–67. doi: 10.1111/nyas.13712
- Debnath M., Berk M., Maes M. Changing dynamics of psychoneuroimmunology during the COVID-19 pandemic. Brain, behavior, & immunity-health. 2020; 5. doi: 100096. 10.1016/j.bbih.2020.100096
- Pisova NV, Pisov AV. Depressiya i posttravmaticheskoe stressovoe rasstroistvo pri novoi koronavirusnoi infektsii. Lechebnoe delo. 2020;(1):82–88.(In Russ). doi: 10.24411/2071-5315-2020-12197
- Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611–627. doi: 10.1016/S2215-0366(20)30203-0
- Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22–34. doi: 10.1038/nri.2015.5
- Brooks SK, Webster RK, Smith LE, et al. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020;395(10227):912–920. doi: 10.1016/S0140-6736(20)30460-8
- Mazza MG, De Lorenzo R, Conte C, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594–600. doi: 10.1016/j.bbi.2020.07.037
- Benedetti F, Mazza M, Cavalli G, et al. Can Cytokine Blocking Prevent Depression in COVID-19 Survivors? J Neuroimmune Pharmacol. 2021;16(1):1–3. doi: 10.1007/s11481-020-09966-z
- Bilbul M, Paparone P, Kim AM, et al. Psychopharmacology of COVID-19. Psychosomatics. 2020;61(5):411–427. doi: 10.1016/j.psym.2020.05.006
- Garcia P, Revet A, Yrondi A, et al. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A Vigi Base Study. Drug Saf. 2020;43(12):1315–1322. doi: 10.1007/s40264-020-01013-3
- Hossain MM, Tasnim S, Sultana A, et al. Epidemiology of mental health problems in COVID-19: a review. F1000Res. 2020;9:636. doi: 10.12688/f1000research.24457.1
- Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord. 2020;277:55–64. doi: 10.1016/j.jad.2020.08.001
- Sakib N, Akter T, Zohra F, et al. Fear of COVID-19 and Depression: A Comparative Study Among the General Population and Healthcare Professionals During COVID-19 Pandemic Crisis in Bangladesh. Int J Ment Health Addict. 2021:1–17. doi: 10.1007/s11469-020-00477-9
- Vindegaard N, Benros ME. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain Behav Immun. 2020;89:531–542. doi: 10.1016/j.bbi.2020.05.048
- Ustun G. Determining depression and related factors in a society affected by COVID-19 pandemic. Int J Soc Psychiatry. 2021;67(1):54–63. doi: 10.1177/0020764020938807
- Bonsaksen T, Heir T, Schou-Bredal I, et al. Post-Traumatic Stress Disorder and Associated Factors during the Early Stage of the COVID-19 Pandemic in Norway. Int J Environ Res Public Health. 2020;17(24). doi: 10.3390/ijerph17249210
- Almeida M, Shrestha AD, Stojanac D, Miller LJ. The impact of the COVID-19 pandemic on women's mental health. Arch Womens Ment Health. 2020;23(6):741–748. doi: 10.1007/s00737-020-01092-2
- Javed B, Sarwer A, Soto EB, Mashwani ZU. The coronavirus (COVID-19) pandemic's impact on mental health. Int J Health Plann Manage. 2020;35(5):993–996. doi: 10.1002/hpm.3008
- Dubey S, Biswas P, Ghosh R, et al. Psychosocial impact of COVID-19. Diabetes Metab Syndr. 2020;14(5):779–788. doi: 10.1016/j.dsx.2020.05.035
- Banerjee D. 'Age and ageism in COVID-19': Elderly mental health-care vulnerabilities and needs. Asian J Psychiatr. 2020;51:102154. doi: 10.1016/j.ajp.2020.102154
- Kholmogorova AB, Petrikov SS, Suroyegina AY, et al. Burnout and its Factors in Healthcare Workers Involved in Providing Health Care for Patients With COVID-19 at Different Stages of the Pandemic. Russian Sklifosovsky Journal "Emergency Medical Care". 2020;9(3):321–337. (In Russ). doi: 10.23934/2223-9022-2020-9-3-321-337
- Mosolov SN. Problems of mental health in the situation of COVID-19 pandemic. Zhurnal nevrologii i psikhiatrii im SS Korsakova. 2020;120(5):7. (In Russ). doi: 10.17116/jnevro20201200517
- Hao F, Tan W, Jiang L, et al. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry. Brain Behav Immun. 2020;87:100–106. doi: 10.1016/j.bbi.2020.04.069
- Navarro C, Yanez AM, Garcia A, et al. Effectiveness of a healthy lifestyle promotion program as adjunctive teletherapy for treatment-resistant major depression during COVID-19 pandemic: A randomized clinical trial protocol. Medicine (Baltimore). 2020;99(45):e22958. doi: 10.1097/MD.0000000000022958
- Luykx JJ, van Veen SMP, Risselada A, et al. Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic. Br J Psychiatry. 2020;217(3):471–474. doi: 10.1192/bjp.2020.92
- Zhang K, Zhou X, Liu H, Hashimoto K. Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders. Br J Psychiatry. 2020;217(1):351. doi: 10.1192/bjp.2020.84
- Chatterjee SS, Malathesh BC, Das S, Singh OP. Interactions of recommended COVID-19 drugs with commonly used psychotropics. Asian J Psychiatr. 2020;52:102173. doi: 10.1016/j.ajp.2020.102173
- Dotson S, Hartvigsen N, Wesner T, et al. Clozapine Toxicity in the Setting of COVID-19. Psychosomatics. 2020;61(5):577–578.
- doi: 10.1016/j.psym.2020.05.025
- Mosolov SN, Malin DI, Tsukarzi EE, Kostyukova EG. Drug therapy for patients with mental disorders who have a coronavirus infection (COVID-19). Sovremennaya terapiya psikhicheskikh rasstroistv. 2020;(2):34–38. (In Russ). doi: 10.21265/PSYPH.2020.18.69.001
- Hamed MGM, Hagag RS. The possible immunoregulatory and anti-inflammatory effects of selective serotonin reuptake inhibitors in coronavirus disease patients. Med Hypotheses. 2020;144:110140. doi: 10.1016/j.mehy.2020.110140
- Drobizhev MY. COVID-19 and Selective Serotonin Reuptake Inhibitors. Clinical Protective Effects of Fluvoxamine in Patients with COVID-19. Nervnye bolezni. 2020;(3):52–56. (In Russ). doi: 10.24411/2226-0757-2020-12230
- Ma K, Wang X, Feng S, et al. From the perspective of Traditional Chinese Medicine: Treatment of mental disorders in COVID-19 survivors. Biomed Pharmacother. 2020;132:110810. doi: 10.1016/j.biopha.2020.110810